Alluvi, previously BI 4744, presents a significant development in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates impressive efficacy in patient assessments, https://alluvi-healthcare469778.ouyawiki.com/user